Trial Profile
An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 Components of a Formulation of MK0524B With That of Zocor and MK0524A Tablets
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Laropiprant/niacin/simvastatin (Primary) ; Niacin/laropiprant; Simvastatin
- Indications Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia; Hypertriglyceridaemia; Low HDL cholesterol
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 28 Jul 2009 New trial record